VP3.15
Based on 3 publication(s) in Google Scholar
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1281681-54-6
- Formule: C20H22N4OS
- Masse moléculaire:366.48
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) VP3.15
More
Activité biologique
IC50: 1.59 μM (PDE7), 0.88 μM (GSK-3)[1]
Chemical Information
-
CAS No. 1281681-54-6
-
Masse moléculaire 366.48
-
Formule C20H22N4OS
-
SMILES
N1(CC/N=C2N=C(C3=CC=CC=C3)N(C4=CC=CC=C4)S/2)CCOCC1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Biol Chem
REDD1-dependent GSK3β signaling in podocytes promotes canonical NF-κB activation in diabetic nephropathy. [Abstract]2025 Jan 27:108244. PMID: 39880090 -
J Biol Chem
REDD1-dependent GSK3β dephosphorylation promotes NF-κB activation and macrophage infiltration in the retina of diabetic mice. [Abstract]2023 Aug;299(8):104991. PMID: 37392853 -
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)